BIOMED COM
Association
Between
BRCA
Status
And
Triple
Negative
Breast
Cancer
6 Nov 2020
The August 2018 issue (9) of Frontiers in Pharmacology published an article entitled "Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis" written by
Haixia Chen, Wu Jianming, Zhihong Zhang, Yong Tang.
Soueces:
Researchgate.net:
Association
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Pubmed.ncbi.nlm.nih.gov:
Association
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Authors Haixia Chen et al in the article (abstract) write:
"Triple-negative breast cancer (TNBC) is a subtype of aggressive breast cancer and characterized by a lack of the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2.
The writers address, "BRCA genes are tumor-suppressor genes that are involved in DNA damage repair and mutations of BRCgenes may increase the risk of developing breast cancer and/or ovarian cancer due to defective DNA repair mechanisms."
The authors add, "However, the relationship between BRCA status and TNBC needs to be further investigated and validated."
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Researchgate.net:
Association
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
The writers note, "The aim of this meta-analysis was to evaluate the association between BRCA status and TNBC."
"We systematically," write the authors, "searched the electronic databases of MEDLINE (PubMed), Embase, and Cochrane Library to identify relevant publications from April, 1959 to November, 2017."
The writers explain, "The data from the studies were examined by a meta-analysis using STATA software to calculate the odds ratio (OR) with 95% confidence interval (CI) by fixed-effect and random-effect models."
The authors point out, "We identified 16 qualified studies from 527 publications with 46,870 breast cancer patients including 868 BRCA1 mutations (BRCA1Mut ) carriers, 739 BRCA2 mutations (BRCA2Mut ) carriers, and 45,263 non-carriers."
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
The writers address, "The results showed that breast cancer patients with BRCA1Mut carriers were more likely to have TNBC than those of BRCA2Mut carriers (OR: 3.292; 95% CI: 2.773-3.909) or non-carriers (OR: 8.889; 95% CI: 6.925-11.410)."
They note, "Furthermore, high expression of nuclear grade and large tumor burden (>2 cm) were significantly more common in breast cancer patients with BRCA1Mutcarriers than those of BRCA2Mut carriers (OR: 2.663; 95% CI: 1.731-4.097; P = 0.211) or non-carriers (OR: 1.577; 95% CI: 1.067-2.331; P = 0.157)."
"The data suggest that breast cancer patients with BRCA1Mutare more likely to have TNBC, high nuclear grade, and larger tumor burden," write the authors.
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Researchgate.net:
Association
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Link:
TheLancet.com:
Mammography
screening
for breast cancer—
the UK Age trial
COVID-19
Metformin
ACE2 Receptor
6 Nov 2020
In the 2020 issue of the Science Direct "sciencedirect.com" authors Atul Malhotra, JohnY-J Shyy published an article entitled "ACE2, Metformin, and COVID-19".
iScience, Volume 23, Issue 9
25 September 2020
The authors write (in the summary) the following words:
"COVID-19 is becoming a leading cause of mortality throughout the world, and few effective therapies are currently available."
The writers address, "Angiotensin converting enzyme 2 (ACE2) is essential to COVID-19 pathogenesis, as the binding of SARS-CoV-2 spike protein (S protein) is required for viral entry and development of COVID-19."
Source:
ACE2,
Metformin,
and COVID-19
The authors write, "ACE2 regulates the protective arm of the renin-angiotensin-aldosterone system (RAAS) that endows anti-hypertensive and anti-inflammatory effects in the cardiovascular and pulmonary systems."
They point out, "Preclinical data suggest ACE2 might be downregulated after SARS-CoV-2 binding, and treatments that increase ACE2 may prevent cardiopulmonary injury."
ACE2,
Metformin,
and COVID-19
The authors note, "Development, testing, and mass production of novel ACE2 therapies may take years, whereas more effective treatments for COVID-19 are needed urgently."
"Metformin is," explain the writers "a widely available anti-diabetic agent that has an excellent safety profile, and clinical and preclinical data suggest metformin may offer cardiopulmonary protection in COVID-19 via enhanced ACE2 expression."
ACE2,
Metformin,
and COVID-19
The authors cite the work of Lan et al., 2020 (Introduction) as they address:
"With the COVID-19 pandemic a threat to human health worldwide, there is an urgent need to identify treatments that are safe and available immediately."
"The virus responsible for COVID-19, SARS-CoV-2, has a spike protein (S protein) binding domain that is nearly identical in structure to the virus responsible for prior outbreaks of severe acute respiratory syndrome (SARS), SARS-CoV-1 (Lan et al., 2020)".
ACE2,
Metformin,
and COVID-19
The authors cite the paper of Wrapp et al., 2020.
According to the paper of Wrapp et al. (2020):
"However, the binding affinity of SARS-CoV-2 for the angiotensin converting enzyme 2 (ACE2) receptor appears to be 10 times stronger, which may partially explain its rapid spread throughout the world".
The authors cite the scientific work of Reddy et al. (2019) who note:
"Interestingly, SARS-CoV-1 was found to decrease ACE2 expression after binding, and low levels of ACE2 have been implicated in various cardiovascular impairments and acute respiratory distress syndrome (ARDS)."
The writers address the work of Monteil et al. (2020) as saying, "Recently, treatment with human recombinant ACE2 (hrACE2) showed positive results in a human organoid model of SARS-CoV-2."
The authors point out, "But safety and efficacy of hrACE2 still need to be determined in human studies and timely production might not meet the need for patients."
ACE2,
Metformin,
and COVID-19
/>
The writers note, "Here, we discuss the rationale for metformin as a safe and currently available therapy that is known to increase ACE2 and may offer cardiopulmonary benefit in patients suffering from COVID-19."
The aurhors cite the work of Chen et al (2020) as they write:
"Data collected from cohorts in Wuhan, China indicate high comorbidity of hypertension, diabetes mellitus (DM), and cardiovascular diseases among patients with COVID-19."
ACE2,
Metformin,
and COVID-19
A citation from the scientific work of Vaduganathan et al. (2020) demonstrates, "The prevalence of hypertension in COVID-19 draws tremendous attention to using RAAS inhibitors, i.e., ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs), in treating COVID-19 symptoms and the underlying diseases."
The writers cite the investigation of
Ferrario et al. in 2005 as they write, "Ample preclinical and clinical studies have been conducted to investigate the effects of ACEI and ARBs on the expression and activity on ACE2."
ACE2,
Metformin,
and COVID-19
The authors cite from the study of Ramchand et al. in 2018 as they address, "However, these studies have generated conflicting results and the effects of these drugs on ACE2 in humans remain inconclusive."
The writers explain, "Nonetheless, consensus is emerging that potential benefits override the potential harms of RAAS inhibitors in COVID-19 Vaduganathan al., 2020, possibly via ACE2 augmentation."
The authors point out, "Despite the American Heart Association statement advocating “not to add or remove any RAAS-related treatments, beyond actions based on standard clinical practice,” we have little knowledge on the benefits or risks of other drugs known to modulate ACE2, such as anti-diabetic agents."
"Amid the comorbidity of diabetes and high body mass index (BMI) in COVID-19, this information is urgently needed," the writers add.
ACE2,
Metformin,
and COVID-19
ASSOCIATION
BETWEEN
BRCA
STATUS
AND
P53
STATUS
IN
BREAST
CANCER
6 Nov 2020
The June 2016 issue of Medical science monitor published an article entitled "Association Between BRCA Status and P53 Status in Breast Cancer: A Meta-Analysis" written by Lin Peng, Tao Xu,Ting Long,Huaiquan Zuo.
Source:
Researchgate.net:
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
Pubmed.ncbi.nlm.nih.gov:
Association
Between
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
Lin Peng et al. address about the background with the following words:
"Research on BRCA mutation has meaningful clinical implications, such as identifying risk of second primary cancers and risk of hereditary cancers."
The authors write, "This study seeks to summarize available data to investigate the association between BRCA status and P53 status by meta-analysis."
The writers talk about the material and methods with the following details:
"We searched PubMed, Embase, and Cochrane library databases for relevant studies."
Researchgate.net:
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
The authors address, "Meta-analysis was conducted using STATA software. We summarized odds ratios by fixed-effects or random-effects models."
The writers talk about their results:
"This study included a total of 4288 cases from 16 articles, which including 681 BRCA1 mutation carriers (BRCA1Mut), 366 carriers of BRCA2 mutation (BRCA2Mut), and 3241 carriers of normal versions of these genes."
"BRCA1Mut was significantly associated with P53 over-expression compared with BRCA2Mut (OR 1.851, 95% CI=1.393-2.458) or non-carriers (OR=2.503, 95% CI=1.493-4.198)," write the authors.
Researchgate.net:
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
The writers address, "No difference was found between p53 protein expression in BRCA2 Mut carriers and non-carriers (OR=0.881, 95% CI=0.670-1.158)."
Finally, the authors write about their conclusion:
"Our meta-analysis suggests that BRCA1Mut breast cancer patients are more likely to have P53 overexpression compared with BRCA2Mut and non-carriers."
"This information provides valuable information for clinicians who perform related studies in the future," the authors address.
Researchgate.net:
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
Clinical outcome of
Breast Cancer
In
Carriers of
BRCA1
And
BRCA1
Mutations
6 Nov 2020
In the 27 April 2020 issue of NATURE authors Solene De Talhouet,Julien Peron,[…] S.Intidhar Labidi-Galy published an article entitled "Clinical outcome of breast cancer in carriers of BRCA1and BRCA2 mutations according to molecular subtypes".
Scientific Reports
volume 10, Article number:
7073(2020)
NATURE:
Clinical outcome of
breast cancer
in carriers of
BRCA1and BRCA2
mutations
according to
molecular subtypes"
A Publisher Correction
to this article was published
on 02 November 2020
Authors Solene De Talhouet,Julien Peron,[…] S.Intidhar Labidi-Galy in an abstract write the following:
"BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents."
NATURE:
Clinical outcome of
breast cancer
in carriers of
BRCA1and BRCA2
mutations
according to
molecular subtypes"
The writers explain, "There are conflicting data regarding the prognostic value of BRCAgermline mutations in breast cancer (BC) patients."
The authors address, "We collected clinical, pathological and genetic data of a cohort 925 BC patients preselected for genetic screening and treated with neoadjuvant or adjuvant chemotherapy, of whom 266 were BRCA carriers."
The writers explain, "Overall, 171 women carried a BRCA1mutation, 95 carried a BRCA2 mutation, and 659 were non-carriers."
They address, "In the entire cohort, there was a prolonged disease-free survival (DFS) for BRCA carriers (hazard ratio (HR) = 0.63; 95% confidence interval (CI), 0.44–0.90 for BRCA1; HR = 0.72; 95%CI, 0.47–1.1 for BRCA2; p = 0.020) and a trend toward prolonged disease-specific survival (DSS; HR = 0.65; 95%CI, 0.40–1.1 for BRCA1; HR = 0.78; 95%CI, 0.44–1.38 for BRCA2; p = 0.19) though not statistically significant."
The authors explain, "In the TNBC group, BRCAcarriers had prolonged DFS (adjusted HR = 0.50; 95%CI, 0.28–0.89 for BRCA1;adjusted HR = 0.37; 95%CI, 0.11–1.25, for BRCA2; p = 0.034) and DSS (adjusted HR = 0.42; 95%CI, 0.21–0.82 for BRCA1;adjusted HR = 0.45; 95%CI, 0.11-1.9 for BRCA2; p = 0.023). In the non-TNBC group, the BRCA1 or BRCA2 mutations did not have any impact on survival."
"These results suggest that BRCA1/BRCA2 germline mutations are associated with prolonged survival only if women were diagnosed with TNBC," the authors conclude.
NATURE:
Clinical outcome of
breast cancer
in carriers of
BRCA1and BRCA2
mutations
according to
molecular subtypes"
Clinical outcome of
breast cancer
in carriers of
BRCA1and BRCA2
mutations
according to
molecular subtypes"
MBC
In
Canada
6 Nov 2020
The website EXTRAORDINARY MOMENTS "extraordinarymoments.ca" writes about the metastatic breast cancer in Canada "MBC IN CANADA".
"In 2017, an estimated 26,300 Canadian women would be diagnosed with breast cancer.[1]
The information in the website addresses the following:
"Of those women, about 10% will have an initial diagnosis of metastatic breast cancer (mBC) and 30% who are first diagnosed with early stage breast cancer will go on to develop mBC."[2]
MBC IN CANADA
According to this infornation in the website "extraordinarymoments.ca":
"For women living with mBC, also known as advanced or Stage IV breast cancer,the cancer has spread beyond the breast to other areas of the body, such as the lungs, liver, bones or brain."[2]
The website's information explains,
"It may happen before or after treatment, or it may develop from reoccurring breast cancer."[3]
It adds, "Although there have been advancements in early detection and treatment, there is still no cure."[4]
The website's information addresses,
"The 5-year relative survival of women diagnosed with mBC is 22%."[4,5]
"However, a small but meaningful number of women may live many years after an initial diagnosis of mBC," the information says. [6]
MBC IN CANADA
Subscribe to:
Posts (Atom)
A. N. DIBA
BIOMED COM Association Between BRCA Status And Triple Negative Breast Cancer 6 Nov 2020 ...
-
BIOMED COM Association Between BRCA Status And Triple Negative Breast Cancer 6 Nov 2020 ...
"Triple-negative breast cancer (TNBC) is a subtype of aggressive breast cancer and characterized by a lack of the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2.
The writers address, "BRCA genes are tumor-suppressor genes that are involved in DNA damage repair and mutations of BRCgenes may increase the risk of developing breast cancer and/or ovarian cancer due to defective DNA repair mechanisms."
The authors add, "However, the relationship between BRCA status and TNBC needs to be further investigated and validated."
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Researchgate.net:
Association
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Researchgate.net:
Association
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
The writers note, "The aim of this meta-analysis was to evaluate the association between BRCA status and TNBC."
"We systematically," write the authors, "searched the electronic databases of MEDLINE (PubMed), Embase, and Cochrane Library to identify relevant publications from April, 1959 to November, 2017."
The writers explain, "The data from the studies were examined by a meta-analysis using STATA software to calculate the odds ratio (OR) with 95% confidence interval (CI) by fixed-effect and random-effect models."
The authors point out, "We identified 16 qualified studies from 527 publications with 46,870 breast cancer patients including 868 BRCA1 mutations (BRCA1Mut ) carriers, 739 BRCA2 mutations (BRCA2Mut ) carriers, and 45,263 non-carriers."
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
The writers address, "The results showed that breast cancer patients with BRCA1Mut carriers were more likely to have TNBC than those of BRCA2Mut carriers (OR: 3.292; 95% CI: 2.773-3.909) or non-carriers (OR: 8.889; 95% CI: 6.925-11.410)."
They note, "Furthermore, high expression of nuclear grade and large tumor burden (>2 cm) were significantly more common in breast cancer patients with BRCA1Mutcarriers than those of BRCA2Mut carriers (OR: 2.663; 95% CI: 1.731-4.097; P = 0.211) or non-carriers (OR: 1.577; 95% CI: 1.067-2.331; P = 0.157)."
"The data suggest that breast cancer patients with BRCA1Mutare more likely to have TNBC, high nuclear grade, and larger tumor burden," write the authors.
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Researchgate.net:
Association
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Link:
TheLancet.com:
Mammography
screening
for breast cancer—
the UK Age trial
Association
Pubmed:
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Researchgate.net:
Association
Between
BRCA Status and
Triple-Negative
Breast Cancer:
A Meta-Analysis"
Link:
TheLancet.com:
Mammography
screening
for breast cancer—
the UK Age trial
COVID-19
Metformin
ACE2 Receptor
6 Nov 2020
In the 2020 issue of the Science Direct "sciencedirect.com" authors Atul Malhotra, JohnY-J Shyy published an article entitled "ACE2, Metformin, and COVID-19".
iScience, Volume 23, Issue 9
25 September 2020
The authors write (in the summary) the following words:
"COVID-19 is becoming a leading cause of mortality throughout the world, and few effective therapies are currently available."
The writers address, "Angiotensin converting enzyme 2 (ACE2) is essential to COVID-19 pathogenesis, as the binding of SARS-CoV-2 spike protein (S protein) is required for viral entry and development of COVID-19."
Source:
ACE2,
Metformin,
and COVID-19
The authors write, "ACE2 regulates the protective arm of the renin-angiotensin-aldosterone system (RAAS) that endows anti-hypertensive and anti-inflammatory effects in the cardiovascular and pulmonary systems."
They point out, "Preclinical data suggest ACE2 might be downregulated after SARS-CoV-2 binding, and treatments that increase ACE2 may prevent cardiopulmonary injury."
ACE2,
Metformin,
and COVID-19
The authors note, "Development, testing, and mass production of novel ACE2 therapies may take years, whereas more effective treatments for COVID-19 are needed urgently."
"Metformin is," explain the writers "a widely available anti-diabetic agent that has an excellent safety profile, and clinical and preclinical data suggest metformin may offer cardiopulmonary protection in COVID-19 via enhanced ACE2 expression."
ACE2,
Metformin,
and COVID-19
The authors cite the work of Lan et al., 2020 (Introduction) as they address:
"With the COVID-19 pandemic a threat to human health worldwide, there is an urgent need to identify treatments that are safe and available immediately."
"The virus responsible for COVID-19, SARS-CoV-2, has a spike protein (S protein) binding domain that is nearly identical in structure to the virus responsible for prior outbreaks of severe acute respiratory syndrome (SARS), SARS-CoV-1 (Lan et al., 2020)".
ACE2,
Metformin,
and COVID-19
The authors cite the paper of Wrapp et al., 2020.
According to the paper of Wrapp et al. (2020):
"However, the binding affinity of SARS-CoV-2 for the angiotensin converting enzyme 2 (ACE2) receptor appears to be 10 times stronger, which may partially explain its rapid spread throughout the world".
The authors cite the scientific work of Reddy et al. (2019) who note:
"Interestingly, SARS-CoV-1 was found to decrease ACE2 expression after binding, and low levels of ACE2 have been implicated in various cardiovascular impairments and acute respiratory distress syndrome (ARDS)."
The writers address the work of Monteil et al. (2020) as saying, "Recently, treatment with human recombinant ACE2 (hrACE2) showed positive results in a human organoid model of SARS-CoV-2."
The authors point out, "But safety and efficacy of hrACE2 still need to be determined in human studies and timely production might not meet the need for patients."
ACE2,
Metformin,
and COVID-19
/>
The writers note, "Here, we discuss the rationale for metformin as a safe and currently available therapy that is known to increase ACE2 and may offer cardiopulmonary benefit in patients suffering from COVID-19."
The aurhors cite the work of Chen et al (2020) as they write:
"Data collected from cohorts in Wuhan, China indicate high comorbidity of hypertension, diabetes mellitus (DM), and cardiovascular diseases among patients with COVID-19."
ACE2,
Metformin,
and COVID-19
A citation from the scientific work of Vaduganathan et al. (2020) demonstrates, "The prevalence of hypertension in COVID-19 draws tremendous attention to using RAAS inhibitors, i.e., ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs), in treating COVID-19 symptoms and the underlying diseases."
The writers cite the investigation of
Ferrario et al. in 2005 as they write, "Ample preclinical and clinical studies have been conducted to investigate the effects of ACEI and ARBs on the expression and activity on ACE2."
ACE2,
Metformin,
and COVID-19
The authors cite from the study of Ramchand et al. in 2018 as they address, "However, these studies have generated conflicting results and the effects of these drugs on ACE2 in humans remain inconclusive."
The writers explain, "Nonetheless, consensus is emerging that potential benefits override the potential harms of RAAS inhibitors in COVID-19 Vaduganathan al., 2020, possibly via ACE2 augmentation."
The authors point out, "Despite the American Heart Association statement advocating “not to add or remove any RAAS-related treatments, beyond actions based on standard clinical practice,” we have little knowledge on the benefits or risks of other drugs known to modulate ACE2, such as anti-diabetic agents."
"Amid the comorbidity of diabetes and high body mass index (BMI) in COVID-19, this information is urgently needed," the writers add.
ACE2,
Metformin,
and COVID-19
ASSOCIATION
BETWEEN
BRCA
STATUS
AND
P53
STATUS
IN
BREAST
CANCER
6 Nov 2020
The June 2016 issue of Medical science monitor published an article entitled "Association Between BRCA Status and P53 Status in Breast Cancer: A Meta-Analysis" written by Lin Peng, Tao Xu,Ting Long,Huaiquan Zuo.
Source:
Researchgate.net:
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
Pubmed.ncbi.nlm.nih.gov:
Association
Between
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
Lin Peng et al. address about the background with the following words:
"Research on BRCA mutation has meaningful clinical implications, such as identifying risk of second primary cancers and risk of hereditary cancers."
The authors write, "This study seeks to summarize available data to investigate the association between BRCA status and P53 status by meta-analysis."
The writers talk about the material and methods with the following details:
"We searched PubMed, Embase, and Cochrane library databases for relevant studies."
Researchgate.net:
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
The authors address, "Meta-analysis was conducted using STATA software. We summarized odds ratios by fixed-effects or random-effects models."
The writers talk about their results:
"This study included a total of 4288 cases from 16 articles, which including 681 BRCA1 mutation carriers (BRCA1Mut), 366 carriers of BRCA2 mutation (BRCA2Mut), and 3241 carriers of normal versions of these genes."
"BRCA1Mut was significantly associated with P53 over-expression compared with BRCA2Mut (OR 1.851, 95% CI=1.393-2.458) or non-carriers (OR=2.503, 95% CI=1.493-4.198)," write the authors.
Researchgate.net:
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
The writers address, "No difference was found between p53 protein expression in BRCA2 Mut carriers and non-carriers (OR=0.881, 95% CI=0.670-1.158)."
Finally, the authors write about their conclusion:
"Our meta-analysis suggests that BRCA1Mut breast cancer patients are more likely to have P53 overexpression compared with BRCA2Mut and non-carriers."
"This information provides valuable information for clinicians who perform related studies in the future," the authors address.
Researchgate.net:
BRCA Status
and P53 Status
in Breast Cancer:
A Meta-Analysis
Clinical outcome of
Breast Cancer
In
Carriers of
BRCA1
And
BRCA1
Mutations
6 Nov 2020
In the 27 April 2020 issue of NATURE authors Solene De Talhouet,Julien Peron,[…] S.Intidhar Labidi-Galy published an article entitled "Clinical outcome of breast cancer in carriers of BRCA1and BRCA2 mutations according to molecular subtypes".
Scientific Reports
volume 10, Article number:
7073(2020)
NATURE:
Clinical outcome of
breast cancer
in carriers of
BRCA1and BRCA2
mutations
according to
molecular subtypes"
A Publisher Correction
to this article was published
on 02 November 2020
Authors Solene De Talhouet,Julien Peron,[…] S.Intidhar Labidi-Galy in an abstract write the following:
"BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents."
NATURE:
Clinical outcome of
breast cancer
in carriers of
BRCA1and BRCA2
mutations
according to
molecular subtypes"
The writers explain, "There are conflicting data regarding the prognostic value of BRCAgermline mutations in breast cancer (BC) patients."
The authors address, "We collected clinical, pathological and genetic data of a cohort 925 BC patients preselected for genetic screening and treated with neoadjuvant or adjuvant chemotherapy, of whom 266 were BRCA carriers."
The writers explain, "Overall, 171 women carried a BRCA1mutation, 95 carried a BRCA2 mutation, and 659 were non-carriers."
They address, "In the entire cohort, there was a prolonged disease-free survival (DFS) for BRCA carriers (hazard ratio (HR) = 0.63; 95% confidence interval (CI), 0.44–0.90 for BRCA1; HR = 0.72; 95%CI, 0.47–1.1 for BRCA2; p = 0.020) and a trend toward prolonged disease-specific survival (DSS; HR = 0.65; 95%CI, 0.40–1.1 for BRCA1; HR = 0.78; 95%CI, 0.44–1.38 for BRCA2; p = 0.19) though not statistically significant."
The authors explain, "In the TNBC group, BRCAcarriers had prolonged DFS (adjusted HR = 0.50; 95%CI, 0.28–0.89 for BRCA1;adjusted HR = 0.37; 95%CI, 0.11–1.25, for BRCA2; p = 0.034) and DSS (adjusted HR = 0.42; 95%CI, 0.21–0.82 for BRCA1;adjusted HR = 0.45; 95%CI, 0.11-1.9 for BRCA2; p = 0.023). In the non-TNBC group, the BRCA1 or BRCA2 mutations did not have any impact on survival."
"These results suggest that BRCA1/BRCA2 germline mutations are associated with prolonged survival only if women were diagnosed with TNBC," the authors conclude.
NATURE:
Clinical outcome of
breast cancer
in carriers of
BRCA1and BRCA2
mutations
according to
molecular subtypes"
Clinical outcome of
breast cancer
in carriers of
BRCA1and BRCA2
mutations
according to
molecular subtypes"
volume 10, Article number:
7073(2020)
to this article was published
on 02 November 2020
MBC
In
Canada
6 Nov 2020
The website EXTRAORDINARY MOMENTS "extraordinarymoments.ca" writes about the metastatic breast cancer in Canada "MBC IN CANADA".
"In 2017, an estimated 26,300 Canadian women would be diagnosed with breast cancer.[1]
The information in the website addresses the following:
"Of those women, about 10% will have an initial diagnosis of metastatic breast cancer (mBC) and 30% who are first diagnosed with early stage breast cancer will go on to develop mBC."[2]
MBC IN CANADA
According to this infornation in the website "extraordinarymoments.ca":
"For women living with mBC, also known as advanced or Stage IV breast cancer,the cancer has spread beyond the breast to other areas of the body, such as the lungs, liver, bones or brain."[2]
The website's information explains,
"It may happen before or after treatment, or it may develop from reoccurring breast cancer."[3]
It adds, "Although there have been advancements in early detection and treatment, there is still no cure."[4]
The website's information addresses,
"The 5-year relative survival of women diagnosed with mBC is 22%."[4,5]
"However, a small but meaningful number of women may live many years after an initial diagnosis of mBC," the information says. [6]
MBC IN CANADA
Subscribe to:
Posts (Atom)
A. N. DIBA
BIOMED COM Association Between BRCA Status And Triple Negative Breast Cancer 6 Nov 2020 ...
-
BIOMED COM Association Between BRCA Status And Triple Negative Breast Cancer 6 Nov 2020 ...